Patents Examined by George W Kosturko
  • Patent number: 10993921
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 4, 2021
    Inventors: John Scott Karolchyk, Mark L. Baum
  • Patent number: 10987318
    Abstract: The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 27, 2021
    Assignee: Institute of Medical Sciences, Chinese Academy of Medical Sciences
    Inventors: Xiaozhong Peng, Yan Hu, Wei Han, Boqin Qiang
  • Patent number: 10980811
    Abstract: Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 20, 2021
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, University of Maryland, Baltimore
    Inventors: Nicolas Paul Sluis-Cremer, Adam Daniel Tomich, Yohei Doi, Eric J. Sundberg, Erik H. Klontz, Steven Fletcher
  • Patent number: 10980808
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 20, 2021
    Assignees: The Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • Patent number: 10968180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 6, 2021
    Assignee: Regenacy Pharmaceuticals, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Patent number: 10966911
    Abstract: To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 6, 2021
    Assignee: Kao Corporation
    Inventors: Daiki Murase, Akira Hachiya, Naoki Oya, Kei Takano, Akiko Kawasaki, Keigo Kawabata
  • Patent number: 10952966
    Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 23, 2021
    Assignee: Gattefosse India Pvt. Ltd.
    Inventors: Nabil Farah, Sunil Bambarkar, Vincent Jannin, Chhanda Kapadia, Mangal Nagarsenker, Meenakshi Venkataraman, Megha Marwah
  • Patent number: 10933064
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 2, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
  • Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Patent number: 10898500
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: January 26, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AG
    Inventors: Olaf Weber, Karl Ziegelbauer
  • Patent number: 10888087
    Abstract: Compositions comprising lactams and non-ionic surfactants, suitable for use as antimicrobial, anti-biofilm and bacteriostatic compositions.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 12, 2021
    Assignee: Conopco, Inc.
    Inventor: Paul Damien Price
  • Patent number: 10882838
    Abstract: Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: January 5, 2021
    Assignee: NORTHEASTERN UNIVERSITY
    Inventors: Alexandros Makriyannis, Ganeshsingh A. Thakur, Rishi Sharma
  • Patent number: 10857122
    Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 8, 2020
    Assignee: IMMUNE MODULATION, INC.
    Inventors: Howard Cottam, Emmanuel Ojo-Amaize, Emeka Nchekwube, Olusola Oyemade
  • Patent number: 10857234
    Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 8, 2020
    Assignee: Endocyte Inc.
    Inventors: Christopher P. Leamon, Iontcho R. Vlahov, Jonathan M. Shillingford, Paul J. Kleindl
  • Patent number: 10813897
    Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 27, 2020
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10815249
    Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 27, 2020
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Andrea Bauer, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Michael Joseph Sizensky, Haitao Zhang
  • Patent number: 10772887
    Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Kagoshima University
    Inventors: Daisuke Kodama, Shuji Izumo
  • Patent number: 10772900
    Abstract: The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 15, 2020
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Daniel P. Beiting, Ana M. Misic, Shelly C. Rankin
  • Patent number: 10766882
    Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: September 8, 2020
    Assignee: YUNGJIN PHARM CO., LTD.
    Inventors: Whee Seong Lee, Mi Jung Lee, Bo Jung Kim, Tae Cheul Roh, Seung Hoon Lee, Kyu Dae Lee, You-Hui Lee, Tae Hwan Kwak
  • Patent number: 10759805
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson